Last reviewed · How we verify
Durvalumab, Tremelimumab and ,FOLFOX
Durvalumab, Tremelimumab and ,FOLFOX is a Small molecule drug developed by Centre Georges Francois Leclerc. It is currently in Phase 1 development.
At a glance
| Generic name | Durvalumab, Tremelimumab and ,FOLFOX |
|---|---|
| Sponsor | Centre Georges Francois Leclerc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Durvalumab, Tremelimumab and ,FOLFOX CI brief — competitive landscape report
- Durvalumab, Tremelimumab and ,FOLFOX updates RSS · CI watch RSS
- Centre Georges Francois Leclerc portfolio CI
Frequently asked questions about Durvalumab, Tremelimumab and ,FOLFOX
What is Durvalumab, Tremelimumab and ,FOLFOX?
Durvalumab, Tremelimumab and ,FOLFOX is a Small molecule drug developed by Centre Georges Francois Leclerc.
Who makes Durvalumab, Tremelimumab and ,FOLFOX?
Durvalumab, Tremelimumab and ,FOLFOX is developed by Centre Georges Francois Leclerc (see full Centre Georges Francois Leclerc pipeline at /company/centre-georges-francois-leclerc).
What development phase is Durvalumab, Tremelimumab and ,FOLFOX in?
Durvalumab, Tremelimumab and ,FOLFOX is in Phase 1.